Efficacy of the HLA-B ∗ 58:01 Screening Test in Preventing Allopurinol-Induced Severe Cutaneous Adverse Reactions in Patients with Chronic Renal Insufficiency—A Prospective Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, H.-W. | - |
dc.contributor.author | Kim, D.K. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Chae, D.-W. | - |
dc.contributor.author | Yang, M.-S. | - |
dc.contributor.author | Oh, Y.K. | - |
dc.contributor.author | Lee, J.P. | - |
dc.contributor.author | Jung, J.-W. | - |
dc.contributor.author | Shin, J. | - |
dc.contributor.author | Hwang, J.H. | - |
dc.contributor.author | Kang, M.-G. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Kwon, S.K. | - |
dc.contributor.author | Kim, H.-Y. | - |
dc.contributor.author | Kim, M.-H. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Ryu, D.-R. | - |
dc.contributor.author | Cho, Y.-J. | - |
dc.contributor.author | Jee, Y.-K. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Lee, E.K. | - |
dc.contributor.author | Kim, J.-Y. | - |
dc.contributor.author | Cho, H.S. | - |
dc.contributor.author | Jeong, Y.Y. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Jun, J.-B. | - |
dc.contributor.author | Park, J.-S. | - |
dc.contributor.author | Kim, G.-H. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Jung, H.-Y. | - |
dc.contributor.author | Lee, J.-M. | - |
dc.date.available | 2019-06-26T01:38:12Z | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 2213-2198 | - |
dc.identifier.issn | 2213-2201 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/26414 | - |
dc.description.abstract | Background: Thus far, human leukocyte antigen (HLA)-B ∗ 58:01 has been recognized as the most important risk factor for allopurinol induced severe cutaneous adverse reactions (SCARs). Objective: To determine the usefulness of prospective screening for the HLA-B ∗ 58:01 allele to identify Korean individuals at risk for SCARs induced by allopurinol treatment. Methods: We prospectively enrolled 542 patients with chronic renal insufficiency (CRI) from 10 hospitals nationwide and performed DNA genotyping to determine whether they carried the HLA-B ∗ 58:01 allele. Of these, 503 HLA-B ∗ 58:01-negative patients (92.8% of total) were treated with allopurinol, and 39 HLA-B ∗ 58:01-positive patients (7.2%) were treated with febuxostat, an alternative drug. The patients then were followed up biweekly for 90 days using a telephone survey to monitor symptoms of adverse drug reactions, including SCARs. As a control, we used the historical incidence rate of allopurinol-induced SCARs in 4002 patients with CRI from the same hospitals who were enrolled retrospectively. Results: Nineteen patients in the prospective cohort developed mild and transient adverse reactions but none showed allopurinol-induced SCARs. By contrast, we identified 38 patients with allopurinol-induced SCARs (0.95%) in the historical control. The difference in the incidence of allopurinol-induced SCARs between the prospective cohort and historical control was statistically significant (0% vs 0.95%, respectively; P =.029). Conclusions: The present study demonstrated the clinical usefulness of the HLA-B ∗ 58:01 screening test before allopurinol administration to prevent allopurinol-induced SCARs in patients with CRI. © 2018 American Academy of Allergy, Asthma & Immunology | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | American Academy of Allergy, Asthma and Immunology | - |
dc.title | Efficacy of the HLA-B ∗ 58:01 Screening Test in Preventing Allopurinol-Induced Severe Cutaneous Adverse Reactions in Patients with Chronic Renal Insufficiency—A Prospective Study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jaip.2018.12.012 | - |
dc.identifier.bibliographicCitation | Journal of Allergy and Clinical Immunology: In Practice, v.7, no.4, pp 1271 - 1276 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000463732500024 | - |
dc.identifier.scopusid | 2-s2.0-85059943172 | - |
dc.citation.endPage | 1276 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1271 | - |
dc.citation.title | Journal of Allergy and Clinical Immunology: In Practice | - |
dc.citation.volume | 7 | - |
dc.type.docType | Article in Press | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Allopurinol | - |
dc.subject.keywordAuthor | Chronic | - |
dc.subject.keywordAuthor | Drug hypersensitivity | - |
dc.subject.keywordAuthor | HLA-B ∗ 58:01 allele | - |
dc.subject.keywordAuthor | Renal insufficiency | - |
dc.subject.keywordPlus | COST-EFFECTIVENESS ANALYSIS | - |
dc.subject.keywordPlus | TOXIC EPIDERMAL NECROLYSIS | - |
dc.subject.keywordPlus | STEVENS-JOHNSON-SYNDROME | - |
dc.subject.keywordPlus | HLA-B | - |
dc.subject.keywordPlus | HYPERSENSITIVITY | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | ALLELE | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.